Free Trial

Tarsus Pharmaceuticals (TARS) News Today

Tarsus Pharmaceuticals logo
$42.98 +0.01 (+0.02%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$43.00 +0.02 (+0.03%)
As of 05/23/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TARS Latest News

Tarsus Pharmaceuticals, Inc. stock logo
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Recommendation of "Buy" from Brokerages
Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) have been assigned a consensus rating of "Buy" from the seven research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, five have issued a bu
Tarsus Pharmaceuticals, Inc. stock logo
Tarsus Pharmaceuticals (NASDAQ:TARS) Cut to Hold at Wall Street Zen
Wall Street Zen cut Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday.
Tarsus Pharmaceuticals, Inc. stock logo
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Purchased by Bank of America Corp DE
Bank of America Corp DE boosted its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 44.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 337,856 shares of the company's stock after buying an addition
Tarsus Pharmaceuticals, Inc. stock logo
59,204 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Purchased by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.
Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm
Tarsus Pharmaceuticals, Inc. stock logo
OMERS ADMINISTRATION Corp Buys Shares of 7,400 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
OMERS ADMINISTRATION Corp bought a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 7,400 shares of the company's stock, valued at
Tarsus Pharmaceuticals, Inc. stock logo
Toronto Dominion Bank Acquires New Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Toronto Dominion Bank bought a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,909,228 shares of the company's stock, va
Tarsus Pharmaceuticals, Inc. stock logo
Millennium Management LLC Increases Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Millennium Management LLC boosted its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 189.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 644,010 shares of the compan
Tarsus Pharmaceuticals, Inc. stock logo
Deutsche Bank AG Raises Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Deutsche Bank AG raised its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 93.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 153,441 shares of the company's s
Tarsus Pharmaceuticals, Inc. stock logo
RTW Investments LP Has $179.21 Million Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
RTW Investments LP trimmed its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 5.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,236,549 shares of the compa
Tarsus Pharmaceuticals, Inc. stock logo
Numerai GP LLC Purchases Shares of 18,668 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Numerai GP LLC purchased a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 18,668 shares of the company's stock, valued at approximately $1
Tarsus Pharmaceuticals, Inc. stock logo
Paradigm Biocapital Advisors LP Has $140.19 Million Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Paradigm Biocapital Advisors LP lifted its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 3.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,531,896 shares of the company's stock
Tarsus Pharmaceuticals, Inc. stock logo
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Northern Trust Corp
Northern Trust Corp increased its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 12.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 357,616 shares of the company's stoc
Tarsus Pharmaceuticals, Inc. stock logo
Integral Health Asset Management LLC Has $19.38 Million Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Integral Health Asset Management LLC reduced its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 6.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 350,000 shares of the com
Tarsus Pharmaceuticals, Inc. stock logo
D. E. Shaw & Co. Inc. Grows Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
D. E. Shaw & Co. Inc. raised its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 100.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 365,544 shares of the company's stock after buying an additio
Tarsus Pharmaceuticals, Inc. stock logo
Ensign Peak Advisors Inc Decreases Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Ensign Peak Advisors Inc reduced its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 2.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 570,056 shares of the company's stock aft
Tarsus Pharmaceuticals, Inc. stock logo
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Schonfeld Strategic Advisors LLC
Schonfeld Strategic Advisors LLC lessened its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 94.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,800 shares of the company's st
Tarsus Pharmaceuticals, Inc. stock logo
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by The Manufacturers Life Insurance Company
The Manufacturers Life Insurance Company lifted its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 42.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,777
Tarsus Pharmaceuticals, Inc. stock logo
Tudor Investment Corp ET AL Takes $769,000 Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Tudor Investment Corp ET AL acquired a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 13,880 shares of the company's stock, valued
Tarsus Pharmaceuticals, Inc. stock logo
Dimensional Fund Advisors LP Sells 62,658 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Dimensional Fund Advisors LP cut its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 15.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 341,305 shares of the company's stock after selling 62,658 sh
Tarsus Pharmaceuticals, Inc. stock logo
Tarsus Pharmaceuticals (TARS) to Release Quarterly Earnings on Wednesday
Tarsus Pharmaceuticals (NASDAQ:TARS) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-tarsus-pharmaceuticals-inc-stock/)
Tarsus Pharmaceuticals, Inc. stock logo
Caxton Associates LP Buys New Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Caxton Associates LP purchased a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 16,588 shares of the company's stock, valued at approximatel
Tarsus Pharmaceuticals, Inc. stock logo
Cutter Capital Management LP Invests $6.23 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Cutter Capital Management LP acquired a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 112,500 shares of the company's stock, valued at approximately $6,229,0
Tarsus Pharmaceuticals, Inc. stock logo
The Goldman Sachs Group Increases Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $51.00
The Goldman Sachs Group increased their target price on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a report on Monday.
Tarsus Pharmaceuticals, Inc. stock logo
Voya Investment Management LLC Purchases 18,000 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Voya Investment Management LLC boosted its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 149.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 30,033 shares of the company's stock after purchasing a
Tarsus Pharmaceuticals, Inc. stock logo
Raymond James Financial Inc. Acquires Shares of 19,999 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Raymond James Financial Inc. purchased a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 19,999 shares of the company's stock, valued at approximately $1,107,000. Raymond James Financia
Tarsus Pharmaceuticals, Inc. stock logo
Freestone Grove Partners LP Makes New $439,000 Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Freestone Grove Partners LP bought a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 7,921 shares of the company's stock, valued at approximately $439,000.
Tarsus Pharmaceuticals, Inc. stock logo
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Down - Here's What Happened
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Down - Should You Sell?
Tarsus Pharmaceuticals, Inc. stock logo
Allostery Investments LP Invests $753,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Allostery Investments LP purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 13,600 shares of the company's stock, valued a
Tarsus Pharmaceuticals, Inc. stock logo
Ally Bridge Group NY LLC Decreases Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Ally Bridge Group NY LLC cut its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 46.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 173,144 shares of the company's stock after selling
Tarsus Pharmaceuticals, Inc. stock logo
Voleon Capital Management LP Makes New Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Voleon Capital Management LP purchased a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 5,266 shares of the company's stock, valued at approximately $2
Tarsus Pharmaceuticals, Inc. stock logo
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Price T Rowe Associates Inc. MD
Price T Rowe Associates Inc. MD increased its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 92.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 460,773
Tarsus Pharmaceuticals, Inc. stock logo
20,811 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Acquired by Artia Global Partners LP
Artia Global Partners LP acquired a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 20,811 shares of the com
Tarsus Pharmaceuticals, Inc. stock logo
Barclays PLC Lowers Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Barclays PLC lowered its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 24.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 74,664 shares of the company's stock after
Tarsus Pharmaceuticals, Inc. stock logo
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Buy" by Brokerages
Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) have been assigned an average rating of "Buy" from the seven brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, five have assigned a buy recom
Get Tarsus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter.

TARS Media Mentions By Week

TARS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

TARS
News Sentiment

1.25

0.75

Average
Medical
News Sentiment

TARS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

TARS Articles
This Week

10

5

TARS Articles
Average Week

Get Tarsus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:TARS) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners